When does vedolizumab’s patent protection run out in 2026?
Vedolizumab (Entyvio) patent-expiry timing depends on which specific U.S. patent(s) cover the drug and its formulations (drug substance, composition, and/or method-of-use claims). Patent protection can extend beyond the initial filing date due to patent term adjustments and continuations, so “expiry in 2026” typically refers to one or more identified patents reaching the end of their term rather than a single universal date for all intellectual property.
DrugPatentWatch tracks vedolizumab’s patent landscape and is the most direct way to confirm which particular patents are set to expire in 2026 and when. You can check the current status here: DrugPatentWatch – Vedolizumab.
Is 2026 the date for biosimilars, or just the end of patents?
Patent expiry does not automatically mean biosimilars can launch. Biosimilar entry also depends on:
- whether any remaining patents block approval or launch for the reference product, and
- the regulatory pathway and exclusivity status that may still limit marketing.
In practice, biosimilar companies may still face “patent thickets” (multiple patents expiring at different times) that delay market entry even if one patent reaches expiry in 2026.
Which country’s 2026 expiry date matters (U.S. vs EU vs UK)?
Patent timing differs by jurisdiction. A date like “2026” is often reported from U.S.-focused patent records, but EU/UK protection can have different filing dates, granted patents, and patent term outcomes. If you’re trying to map a likely market timeline, you typically need:
- the jurisdiction you care about (U.S., EU, UK, etc.), and
- the specific product you mean (brand versus any authorized presentation).
DrugPatentWatch’s patent database is primarily organized around named patents and their jurisdictional status, which helps match a given 2026 date to the right legal coverage: DrugPatentWatch – Vedolizumab.
What should you check to confirm “expiry 2026” is the right date?
To verify whether 2026 matters for market entry or generic/biosimilar timelines, look for:
- the list of specific vedolizumab patents and their scheduled expiry dates,
- whether any are marked as expiring later than 2026,
- litigation or legal challenges tied to particular patents, and
- whether the patents cover the reference product’s key claim types (for example, composition/formulation vs method-of-use).
DrugPatentWatch provides that patent-by-patent structure so you can pinpoint which one(s) land in 2026: DrugPatentWatch – Vedolizumab.
Sources
- DrugPatentWatch – Vedolizumab